上药康德乐（重庆）医药有限公司（以下简称“公司”）是上海市国资委管理的上海医药集团所属控股子公司。母公司上海医药集团系全国医药行业龙头企业，业务涵盖医药研发、生产制造、分销零售、投资全产业链。2020年跨入世界500强企业，排名473位，位列中国上市企业（A+H）500强排名57位，全球制药工业TOP48、全球制药品牌TOP24、中国制药工业前三甲。2019年实现营业收入1866亿元，位列中国制造业企业500强排名第43位，人民日报“中国品牌发展指数”100榜单排名第93位，全球制药品牌价值第25位。
SPH KDL Health (Chongqing) Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is a holding subsidiary of SPH Group, which is managed by the State-owned Assets Supervision and Administration Commission of Shanghai Municipality. The parent company, Shanghai Pharma Group, is a leading enterprise in the pharmaceutical industry in China. Its business covers the whole industrial chain of pharmaceutical research and development, manufacturing, distribution and retail, and investment. In 2020, it will become one of the top 500 enterprises in the world, ranking 473, ranking 57 among the top 500 listed enterprises in China (A+H), Top 48 in the global pharmaceutical industry, Top 24 in the global pharmaceutical brands, and Top 3 in the Chinese pharmaceutical industry. In 2019, the company achieved an operating income of 186.6 billion yuan, ranking the 43rd among the top 500 Chinese manufacturing enterprises, the 93rd among the "China Brand Development Index" 100 listed by the People's Daily, and the 25th in the global pharmaceutical brand value.
重庆公司成立于1993年，其前身为重庆医药管理局下属重庆市医药开发公司，公司注册资金5000万，位于九龙坡区科园二路137号，员工115人，公司致力于药品、医疗器械等供应链多元化服务，是重庆市主流医药流通企业，位列重庆药品交易所医疗机构交易配送金额排名第二位，得到上千家厂家授权，可配送超过15000多个品规。公司也是九龙坡区***一家全国性医药流通企业，连续两届作为九龙坡区联合体指定配送会员之一，承担九龙坡区22个医疗机构近千个品规药品保障供应。
Chongqing Company was established in 1993, formerly known as Chongqing Pharmaceutical Development Company under Chongqing Pharmaceutical Administration, with a registered capital of 50 million, located in No. 137 Keyuan Second Road, Jiulongpo District, with 115 employees. The company is committed to diversified supply chain services such as drugs and medical devices, and is the mainstream pharmaceutical circulation enterprise in Chongqing. Ranked the second place in the transaction and distribution amount of medical institutions of Chongqing Drug Exchange. Authorized by thousands of manufacturers, it can deliver more than 15,000 product rules. The company is also the only national pharmaceutical circulation enterprise in jiulongpo district, as one of the designated distribution members of jiulongpo district union for two consecutive terms, it undertakes the security supply of nearly a thousand products of drugs in 22 medical institutions in jiulongpo district.
公司先后荣获“重庆医药行业协会副会长单位”“重庆医保研究会副会长单位”“重庆市九龙坡工商联医药商会副会长单位”“九龙坡区模范示范批发企业”等称号，多次接受国家药监局，区政府、区人大等领导视察指导。
The company has been awarded the titles of "Vice Chairman Unit of Chongqing Pharmaceutical Industry Association", "Vice Chairman Unit of Chongqing Medical Insurance Research Association", "Vice Chairman Unit of Chongqing Jiulongpo Pharmaceutical Chamber of Commerce" and "Jiulongpo District Model and Demonstration Wholesale Enterprise", etc., and has been inspected and guided by State Food and Drug Administration, District Government and District People's University for many times.
2020年公司实现营业收入15.6亿元（含税），解缴税金1669万元。2020年疫情期间，被列为“重庆市防疫物资储备单位”，为我市抗击疫情贡献了积极力量，获得“同心抗疫”特别贡献企业称号。
In 2020, the company will achieve an operating income of 1.56 billion yuan (including tax), and the tax payable will be 16.69 million yuan. During the epidemic period in 2020, the company was listed as the "Chongqing Epidemic Prevention Materials Reserve Unit", which made a positive contribution to the city's fight against the epidemic, and won the title of Special Contribution Enterprise of "Concordant Anti-Epidemic".
公司将继续依托上海医药集团强大的总部资源，以客户为导向的服务理念、合规，诚信透明的管理要求，更好履行服务医改、服务社会的国企责任，保障民生，服务辖区广大患者，为九龙坡区医药卫生改革作出新的贡献。
The company will continue to rely on the strong headquarter resources of SPH Group, customer-oriented service concept, compliance, integrity and transparency management requirements, better fulfill the state-owned responsibility of serving medical reform and serving the society, protect people's livelihood, serve the majority of patients in the area, and make new contributions to the medical and health reform of Jiulongpo District.